Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563 1574. 160. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kes niemi YA, Sullivan D, Hunt D, Colman P, d Emden M, Whiting M, Ehnholm C, Laakso M; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardio- vascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849 1861. doi: 10.1016/S0140-6736(05)67667-2. 161. Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol. 2013;62:1909 1910. doi: 10.1016/j.jacc.2013.07.025. 162. Rod s-Cabau J, Facta A, Larose E, DeLarochelli re R, D ry JP, Nguyen CM, Roy L, Proulx G, Gleeton O, Barbeau G, No l B, Rouleau J, Boudreault JR, Bertrand OF. Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting. Am J Cardiol. 2007;100:640 645. doi: 10.1016/j.amjcard.2007.03.080. 163. Foody JM, Ferdinand FD, Pearce GL, Lytle BW, Cosgrove DM, Sprecher DL. HDL cholesterol level predicts survival in men after coro- nary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circulation. 2000;102(suppl 3):III90 III94. 164. Sabik JF 3rd, Blackstone EH, Gillinov AM, Smedira NG, Lytle BW. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation. 2006;114(suppl):I454 I460. doi: 10.1161/ CIRCULATIONAHA.105.001149. 165. Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, Rosenberg Y, Geller NL. Prognostic factors for athero- sclerosis progression in saphenous vein grafts: the Postcoronary Artery Bypass Graft (Post-CABG) trial: Post-CABG Trial Investigators. J Am Coll Cardiol. 2000;36:1877 1883. 166. Jerzewski K, Ruel M, Voisine P, Le May MR, Kulik A. 